AbbVie-Genmab Lymphoma Drug Fails Phase 3 Trial, Missing Survival Goal
ABBV sits 37% above its 52-week low of $186.77.
Summary
Epcoritamab, co-developed by AbbVie and Genmab, failed to meet the overall survival primary endpoint in the Phase 3 EPCORE DLBCL-1 trial for relapsed/refractory diffuse large B-cell lymphoma. The trial compared epcoritamab monotherapy against standard chemoimmunotherapy regimens in patients ineligible for stem cell transplant. This is a clear setback for AbbVie's oncology pipeline, particularly after recent positive momentum from Rinvoq data and the Apogee acquisition. The failure raises questions about the drug's competitive profile in a crowded lymphoma market. AbbVie had previously disclosed topline results in January without specifying the miss, making this clarification materially negative. With the stock near its 52-week high, this could trigger profit-taking as the market reassesses pipeline value.
At the time of this announcement, ABBV was trading at $255.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $453.9B. The 52-week trading range was $186.77 to $261.64. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.